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Abstract
Background
Urological complications associated with sickle cell disease (SCD), include nocturia, enure-
sis, urinary infections and urinary incontinence. However, scientific evidence to ascertain
the underlying cause of the lower urinary tract symptoms in SCD is lacking.
Objective
Thus, the aim of this study was to evaluate urinary function, in vivo and ex vivo, in the Berke-
ley SCD murine model (SS).
Methods
Urine output was measured in metabolic cage for both wild type and SS mice (25-30 g).
Bladder strips and urethra rings were dissected free and mounted in organ baths. In isolated
detrusor smooth muscle (DSM), relaxant response to mirabegron and isoproterenol (1nM-
10μM) and contractile response to (carbachol (CCh; 1 nM-100μM), KCl (1 mM-300mM),
CaCl2 (1μM-100mM), α,β-methylene ATP (1, 3 and 10 μM) and electrical field stimulation
(EFS; 1-32 Hz) were measured. Phenylephrine (Phe; 10nM-100μM) was used to evaluate
the contraction mechanism in the urethra rings. Cystometry and histomorphometry were
also performed in the urinary bladder.
Results
SSmice present a reduced urine output and incapacity to produce typical bladder contrac-
tions and bladder emptying (ex vivo), compared to control animals. In DSM, relaxation in
response to a selective β3-adrenergic agonist (mirabegron) and to a non-selective β-adren-
ergic (isoproterenol) agonist were lower in SS mice. Additionally, carbachol, α, β-methylene
ATP, KCl, extracellular Ca2+ and electrical-field stimulation promoted smaller bladder
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contractions in SS group. Urethra contraction induced by phenylephrine was markedly
reduced in SS mice. Histological analyses of SS mice bladder revealed severe structural
abnormalities, such as reductions in detrusor thickness and bladder volume, and cell
infiltration.
Conclusions
Taken together, our data demonstrate, for the first time, that SS mice display features of
urinary bladder dysfunction, leading to impairment in urinary continence, which may have
an important role in the pathogenesis of the enuresis and infections observed the SCD
patients.
Introduction
Sickle cell disease (SCD), an inherited disorder of hemoglobin synthesis, is caused by a single
nucleotide substitution (GTG for GAG) in the sixth codon of the β-globin gene. This mutation
results in the substitution of valine for glutamic acid on the surface of the variant β-globin
chain [1]. The multiple pleiotropic effects of the abnormal hemoglobin S production include
vaso-occlusive crisis, stroke, pulmonary hypertension, osteonecrosis, leg ulcers and priapism
[1–3]. SCD-associated urological complications have also been described, such as nocturia,
enuresis, increased frequency of urinary infections and urinary incontinence [4]. Among the
SCD patients presenting urinary tract infection, one to two thirds exhibit recurrent infection
that may be accompanied by fever [5]. There is also an increased incidence of urinary tract
infection during pregnancy in sickle cell trait and SCD [6–9]. As part of the renal complications
of sickling, renal medullary infarcts lead to decreased ability to concentrate urine, yielding
higher daily urinary volumes [10], compensatory polydipsia, and possibly the need for noctur-
nal bladder voiding [4]. Additionally, in SCD, there is a strong association between enuresis
and overactive bladder symptoms such as daytime incontinence, urgency and frequency [11–
15]. However, scientific evidence to ascertain the underlying cause of the lower urinary tract
symptoms (LUTS) in SCD patients is lacking. Some hypotheses to explain LUTS in these
patients include inability of the kidneys to concentrate urine, social and genetic factors, delays
in neurophysiological development, and urinary bladder dysfunction [16, 17] [4, 18].
The abilities of the lower urinary tract to store and to release urine are regulated by neural
circuits located in the brain, spinal cord and peripheral ganglia. The sacral parasympathetic
outflow provides the main excitatory input to the urinary bladder via the release of both cholin-
ergic and non-adrenergic, non-cholinergic transmitters [19–21]. Detrusor smooth muscle
(DSM) expresses muscarinic M2 and M3 receptors in a variety of animal species, but M3 recep-
tors have been reported to be functionally more important for urinary bladder contractions
and efficient emptying than M2 receptors [22, 23]. Non-cholinergic excitatory transmission
mediated by ATP via purinergic P2X receptors in DSMmay also contribute to bladder contrac-
tions [24]. Sympathetic innervation of the bladder arises in the thoracolumbar outflow of the
spinal cord and releases noradrenaline, which activates inhibitory β-2 and β-3 adrenoceptors
in DSM, causing bladder relaxation and contributing to the urine storage phase [19]. In addi-
tion, sympathetic stimulation will also stimulate α1-adrenoceptors in the urethra to provide
bladder outlet resistance and prevent involuntary leakage of urine [25]. Changes to the contrac-
tile and relaxant mechanisms of the urethra and DSMmay lead to either overactive or underac-
tive bladder, depending on the stage of the disease [26].
Underactive Bladder in Sickle Mice
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Several murine models have been developed to mimic human SCD. The Berkeley murine
model of SCD which expresses human sickle hemoglobin exclusively is a well-accepted animal
model that displays most of the clinical features of humans SCD [27, 28], including priapism,
the most prominent urogenital manifestation of SCD. Since little is known of the pathophysiol-
ogy of other urogenital disorders in SCD, we have sought to use the same animal model to
gather further information on how SCD affects bladder function. Therefore, in the present
study, we have used the Berkeley murine model to characterize DSM dysfunction in vivo, inves-
tigate urethra contractile response, receptor-dependent and receptor-independent contractile-
and relaxant-responses in the DSM ex vivo, and urinary bladder structure in SCD.
Materials and Methods
Ethics Statement
All experimental procedures in this study were carried out in accordance with the general ethi-
cal guidelines for animal use established by the Brazilian Society of Laboratory Animal Science
(SBCAL) and EC Directive 86/609/EEC for Animal Experiments and were approved by an
institutional Committee for Ethics in Animal Experimentation of the University Of Campinas
(IACUC/CEEA-UNICAMP, Permit number 1864–1). The animals were euthanized with an
overdose of sodium pentobarbital (1mg/g) and all efforts were made to minimize animal
suffering.
Animals
Berkeley transgenic sickle cell mice (SS mice), expressing exclusively human sickle hemoglobin
((Tg(Hu-miniLCRα1GγAγδβS)Hba0//Hba0Hbb0//Hbb0]; [27]) and C57BL/6 control mice
were used for these studies (20–25 g). The animals were obtained from Jackson Laboratories
(Bar Harbor, ME, USA) and were generated and characterized at the Multidisciplinary Center
for the Investigation of Biological Science in Laboratory Animals of State the University of
Campinas (UNICAMP) and were maintained at constant room temperature on a 12 h light/
dark cycle, with free access to food and water.
Urine output measurement in metabolic cage
Mice (4 in each group) were individually housed in metabolic cages (Cat No. 3701M081, Tec-
niplast, Buguggiate, VA, Italy) with a floor area of 200 cm2 (dimensions 32 X 25 X 36.5 cm,
length X width X height). Mice were fed and received water ad libitum and, after 24 h in the
metabolic cages, weight and 24h urinary volume were recorded.
In vivo cystometry
Mice were anaesthetized with intraperitoneal urethane (1.8 g/kg). Once surgical anesthesia was
reached, a 1 cm incision was made along the midline of the abdomen. The bladder was exposed
and a butterfly cannula (25 G) was inserted into the bladder dome. The cannula was connected
to a three-way tap. One port was connected to a pressure transducer and another to an infusion
pump through a catheter (PE50). Before starting cystometry, the bladder was emptied through
the third port. Continuous cystometry was performed by infusing saline into the bladder at a
rate of 0.6 mL/h. The following parameters were assessed: threshold pressure (TP; intravesical
pressure immediately before micturition); post-void pressure (PVP; intravesical pressure
immediately after micturition); peak pressure (PP; highest intravesical pressure during
micturition); capacity (CP; volume of saline needed to induce the first micturition); compliance
(CO; CP to TP ratio); frequency of voiding contractions (VC) and frequency of non-voiding
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contractions (NVCs). NVCs were defined as spontaneous bladder contractions greater than 4
mmHg from the baseline pressure that did not result in micturition. Bladders from mice used
for cystometry were not used in other experiments.
Ex vivo functional studies
The urinary bladder and urethra were surgically removed and placed in chilled Krebs-Henseleit
buffer (118mM NaCl, 25mM NaHCO3, 5.6mM glucose, 4.7mM KCl, 1.2mM KH2PO4,
1.17mMMgSO4.7H2O and 1.17mM CaCl2.2H2O). After removal of the trigone, the DSM was
cleaned of connective and adventitial tissues, and two strips (1.0 x 0.2 x 0.2 cm) of bladder were
obtained from each animal. The strips had intact urothelium, and the urethra was removed
and cut into rings (1 to 1.5 mm in length). The DSM strips were mounted in a 10mL organ sys-
tem and the urethra rings were mounted in 5mL organ baths, both containing Krebs solution
at 37°C, that was continuously bubbled with a mixture of 95% O2 and 5% CO2. DSM strips
were vertically suspended between two metal hooks. One hook was connected to a force trans-
ducer (Ugo Basile, Varese, Italy) and the other acted as a fixed attachment point. Tissues were
allowed to equilibrate for 60 min under a resting tension of 5 mN. For the urethra rings, the
resting tension was adjusted to 2 mN at the beginning of the experiments. The equilibration
period was 45 minutes, and the bathing medium was changed every 15 minutes until the start
of the experiment. Changes in isometric force were recorded using a Power Lab v.7.2 system
(ADInstruments, Sydney, Australia).
Concentration–response curves
To verify the viability of the preparations, high extracellular K+ solution (80 mM, achieved by
substituting NaCl in Krebs buffer for an equimolar concentration of KCl) was added to the
baths at the end of the equilibration time. To evaluate the contraction mechanism of DSM
strips, the full muscarinic agonist carbachol (0.01 to 100 μM) and a hyperpolarizing solution of
KCl (1 to 300 mM) were used to obtain cumulative concentration-response curves in half-log
steps. Non-cumulative concentration–response curves to the purinergic P2X receptor agonist,
αβ-methylene ATP (1, 3 and 10 μM), were also obtained. For the evaluation of the relaxation
mechanism, cumulative concentration–response curves to the non-selective β-adrenergic ago-
nist isoproterenol (0.001–10 μM), and the selective β3-adrenoceptor agonist, mirabegron
(0.001–10 μM), were obtained from DSM strips precontracted with carbachol (1 μM for con-
trol mice and 3 μM for SS mice). To evaluate the contraction mechanism of urethra rings, the
α1-adrenoceptor agonist phenylephrine (0.01 to 100 μM) was used to obtain cumulative con-
centration-response curves in half-log steps. Nonlinear regression analysis to determine the
potency (pEC50) was performed using GraphPad Prism (GraphPad Software, San Diego, CA,
USA) with the constraint that F = 0. All concentration–response data were evaluated for a fit
to a logistics function in the following formula:
E ¼ Emax=½1þ ð10c=10xÞn þ F
where E is the maximum response produced by agonists; c is the logarithm of the EC50, the
concentration of drug that produces a half-maximal response; x is the logarithm of the concen-
tration of the drug; n is a curve-fitting parameter that defines the slope of the concentration
response line; and F is the response observed in the absence of added drug. Values of pEC50
and maximal response (Emax) were expressed as mean ± SEM of N experiments. Emax data
were normalized to the wet weight of the respective urinary bladder strips, and the values of
Emax were represented as mN per milligram wet weight.
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Concentration response curves to extracellular CaCl2
To evaluate the receptor-independent, direct effects of extracellular Ca2+ influx on bladder con-
traction, cumulative concentration response curves to CaCl2 (0.01 to 100 mM) under depolar-
izing conditions were obtained. Bladder strips were prepared and mounted in 10mL organ
baths containing Krebs–Henseleit Ca2+-free solution containing 1mM EGTA to sequester Ca2+
ions, and cyclopiazonic acid (CPA, 10 μM) to deplete sarcoplasmic reticulum Ca2+ stores. Bath
solution was removed and replaced by Krebs–Henseleit Ca2+-free solution containing KCl (80
mM) and CPA (10 μM). After an equilibration period of 15 min, the cumulative curve to CaCl2
was obtained [29].
Electrical field stimulation
Electrical field stimulation (EFS) was applied to bladder strips placed between two platinum
ring electrodes connected to a Grass S88 stimulator (Astro-Med Industrial Park, West War-
wick, RI, USA). EFS was conducted at 80 V, 1 ms pulse width and trains of stimuli lasting 10 s
at varying frequencies (1–32 Hz), with 3 min interval between stimulations. Subsequently, after
incubation periods of 30 min, frequency–response curves were repeated in the presence of the
muscarinic receptor antagonist atropine (1 μM) and/or the P2X receptor blocker suramin
(100 μM), to confirm that the responses were mediated by muscarinic (acetylcholine; ACh)
and P2X (ATP) receptor activation (B; [29]).
Histological Analysis
The animals were euthanized by deep anesthesia before removal of the bladder. Bladders were
split longitudinally for histological processing. The tissues were fixed in 10% formaldehyde solu-
tion for 24 h and subsequently dehydrated in a graded ethanol and xylol series, then embedded
in Histosec (Merck, Rio de Janeiro, RJ, Brazil). Sample tissue sections of 5 μm thick were deparaf-
finized and stained with hematoxylin and eosin for examination by light microscopy. Histologi-
cal analyses were performed by two pathologists blinded to the origin of the specimens.
Drugs
Atropine, carbachol, cyclopiazonic acid, isoflurane, isoproterenol, mirabegron, phenylephrine,
suramin, urethane and α,β-methylene ATP were obtained from Sigma Chem Co. (St. Louis,
MO, USA).
Statistical analysis
Data are expressed as mean ± SEM of n experiments. In the non-cumulative-, cumulative-con-
centration- and frequency–response curves, data are expressed as means of the contraction in
mNmg-1 of wet strip weight ± SEM of n experiments to control for differences in size between
bladder strips. Statistical software Instat (GraphPad Inc., USA) was used for statistical analysis.
Two-way analysis of variance and Student’s t-test were used to evaluate the results. P< 0.05
was accepted as significant.
Results
Urine output is reduced in SS mice
After 24 h of restraint in the metabolic cages, water intake did not change in SS, compared with
the control group (n = 4, respectively; data not shown). However, SS mice presented a significant
reduction in urine output (0.92 ± 0.23 ml), when compared to control mice (1.98 ± 0.38 ml).
Underactive Bladder in Sickle Mice
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Cystometry reveals that SS mice exhibit an underactive bladder
In the cystometric study, control mice showed regular micturition cycles with rare non-voiding
contractions (n = 8; Table 1; Fig 1A). All of the parameters measured were comparable with
our previous data for cystometry in control mice (Leiria et al., 2011). However, homozygous SS
mice showed an atypical voiding pattern characterized by an incapacity to produce typical
bladder contractions and bladder emptying during a 50-min observation. As shown in Fig 1B,
the intravesical pressure during the filling phase increased progressively until reaching a pres-
sure that caused urine leakage (n = 7; Table 1).
Bladders from SSmice have reduced relaxation and contraction
response ex vivo
The cumulative addition of the isoproterenol or mirabegron produced concentration-dependent
DSM relaxations in both control and SS groups (Fig 2A and 2B). Relaxation responses both to
isoproterenol and mirabegron were significantly lower in DSM from SS mice (Emax:
49.1 ± 2.3%; Emax: 73.2 ± 7.0%; n = 4; P<0.05, respectively), when compared with the respective
control mice (Emax: 56.7 ± 1.6%; Emax: 95.8 ± 4.8%; n = 4). No differences in the pEC50 values
for isoproterenol or mirabegron were found between the control (7.00 ± 0.12; 6.64 ± 0.20; n = 4,
respectively) and SS groups (6.94 ± 0.19; 6.20 ± 0.24; n = 4, respectively) (Fig 2A and 2B).
Both the muscarinic agonist (carbachol) and the P2X receptor agonist (α, βmethylene ATP)
produced concentration-dependent DSM contractions in the control and SS groups (Fig 3A and
3B). However, maximal carbachol-induced DSM contractions were markedly lower in SS mice
(0.49 ± 0.06 mN.mg-1; n = 9; P<0.01), when compared with the control group (1.18 ± 0.15 mN.
mg-1; n = 6). No differences in the potency (pEC50) values for carbachol were found between the
control (5.70 ± 0.17; n = 6) and SS (5.81 ± 0.23; n = 9) groups. A similar reduction was seen with
the maximal response to α, βmethylene ATP (P<0.001, n = 4 for each group).
In the evaluation of receptor-independent stimulation, cumulative addition of KCl produced
concentration-dependent DSM contractions. The maximal contractions were significantly lower
Table 1. General, cystometric andmorphologic parameters for control and SSmice.
Parameters Control Homozygous (SS)
Body weight (g) 24.6 ± 1.54 25.4 ± 1.67
Cystometric data
Threshold Pressure (ThP, mmHg) 6.25 ± 0.82 -
Capacity (mL) 0.24 ± 0.03 -
Compliance (mL/mmHg) 0.027 ± 0.002 -
Peak Pressure (mmHg) 12.45 ± 1.69 -
Frequency (n° of voidings/min) 0.18 ± 0.03 -
NVCs (n° of NVCs/min) 0.07 ± 0.03 -
Post Void Pressure (mmHg) 0.90 ± 0.53 -
Morphologic data
Urinary bladder weight (mg) 26.6 ± 1.55 17.5 ± 2.21 **
Urothelium thickness (mm) 0.041 ± 0.004 0.031 ± 0.002
Detrusor thickness (mm) 0.37 ± 0.04 0.26 ± 0.03 **
Bladder volume (mm3) 17.8 ± 1.83 4.8 ± 0.55 **
Data represent the means ± SEM for 8–14 mice.
** P<0.01.
doi:10.1371/journal.pone.0133996.t001
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in DSM from SS mice (Emax: 0.85 ± 0.08 mN.mg-1; n = 8; P<0.01), when compared with the
control mice (Emax: 1.48 ± 0.20 mN.mg-1; n = 8; Fig 2C). No differences in the pEC50 values for
KCl were found between the control (1.22 ± 0.13; n = 8) and SS groups (1.04 ± 0.20; n = 8; Fig
3C). DSMmaximal contractions to CaCl2 were significantly reduced in strips from SS mice
(1.42 ± 0.08 mN.mg-1; n = 4; P<0.01), compared with those from control mice (2.07 ± 0.13 mN.
mg-1; n = 4; Fig 3D). No differences in the pEC50 values for CaCl2 were found between the con-
trol (4.94 ± 0.03; n = 4) and SS groups (5.04 ± 0.05; n = 4; Fig 3D).
Urethra from SS mice have a reduced contractile response ex vivo
The cumulative addition of the phenylephrine produced concentration-dependent urethra ring
contractions in both the control and SS groups. However, maximal phenylephrine-induced
urethra contractions were markedly lower in SS mice (25.01 ± 8.68 mN.mg-1; n = 4; P<0.001),
when compared with the control group (89.47 ± 2.35 mN.mg-1; n = 6; data not shown).
The DSM response to electrical-field stimulation is reduced in SS mice
and is partially mediated by acetylcholine and ATP
Electrical-field stimulation (EFS) produced frequency-dependent DSM contractions in both
groups, which were significantly reduced in the SS group at the highest frequencies employed
(16 and 32 Hz; P<0.05; Fig 4). Pretreatment of DSM preparations with the muscarinic and puri-
nergic receptor combined reduced the EFS-induced DSMmaximal contractions by approxi-
mately 60% in both groups studied (P<0.01). In controls, maximal contractions decreased from
Fig 1. Representative cystometric recording from control (A) and Berkeley transgenic sickle cell (SS)
mice (B). Arrows in the cystometric trace indicate the micturition peaks.
doi:10.1371/journal.pone.0133996.g001
Underactive Bladder in Sickle Mice
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23.8 ± 3.8 to 10.36 ± 1.9 mN (n = 5), and in SS mice, from 11.8 ± 2.1 to 5.2 ± 1.4 mN (n = 6),
confirming that EFS-elicited contractions are mediated, in part, by ACh and ATP.
Urinary bladders of SS mice suffer morphological changes
Light microscopy of bladders from normal mice confirmed an absence of structural abnormali-
ties (Fig 5A and 5B). Bladders from SCD mice presented with severe lesions and significant
Fig 2. Concentration-response curves from isoproterenol (A) andmirabegron (B) in detrusor smooth
muscle strips from control (A) and Berkeley transgenic sickle cell (SS) mice (B) precontracted by
carbachol (1 μM for control mice and 3 μM for SSmice). Experimental values were calculated relative to
the maximal changes from the contraction produced by carbachol in each tissue, which was taken as 100%.
Data represent the means ± SEM of N experiments. *P < 0.05 compared with control group.
doi:10.1371/journal.pone.0133996.g002
Underactive Bladder in Sickle Mice
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reductions in detrusor thickness and bladder volume, when compared to those of control mice
(Table 1). Infiltration by inflammatory cells (mononuclear cells) in the submucosa and muscu-
lar area was also seen in the tissue of SCD mice (Fig 5C and 5D). In some samples, there was
also the presence of hemorrhage (Fig 5E and 5F) and edema (Fig 5C–5F).
Discussion
Urogenital disorders in SCD have been extensively explored both in the clinic and in experi-
mental research regarding the pathophysiology and treatment of priapism, both in humans
and in mouse models. Nonetheless, urinary bladder dysfunction (UBD) has not been the focus
of extensive research, and clinical data on this matter is scant. Our data show for the first time
that, in addition to chronic hemolytic anemia, vaso-occlusion, and priapism, the Berkeley SCD
mouse model also exhibits a characteristic UBD.
The urinary bladder has two important functions: urine storage and emptying, and both of
these seem to be abnormal in SS mice. A main physiological mechanism to induce DSM relaxa-
tion needed to allow bladder filling under low pressure is β-adrenoceptor stimulation, which,
in most species including humans, involves a strong β3-component [25]. The reduced response
to selective (mirabegron) and non-selective (isoproterenol) beta-adrenergic stimulation in
bladder strips from SS mice suggests that relaxation is reduced in this model.
Micturition occurs when sympathetic fibers are activated during the filling process and the
central nervous system recognizes bladder fullness switching from the stimulation of sympathetic
Fig 3. Detrusor smoothmuscle contraction in response to the muscarinic agonist carbachol (A), the P2X agonist α,β-methylene ATP (B),
potassium chloride (C) and calcium chloride (D) in bladder strips from control and Berkeley transgenic sickle cell (SS) mice.Data represent the
means ± SEM of N experiments. **P < 0.01; ***P < 0.001 compared with control group.
doi:10.1371/journal.pone.0133996.g003
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fibers to parasympathetic fibers [30]. ATP is co-stored and released together with the main neu-
rotransmitter acetylcholine (Ach) [31, 32], contributing to nerve-mediated bladder contraction
and urine elimination [33, 34]. Acetylcholine receptor M3 and ionotropic P2X1 receptors are
responsible for the contractile response in the urinary bladder [20]. Our data show that both
muscarinic and purinergic blockade reduce, but do not abolish DSM contraction, highlighting
DSM hypoactivity, but also corroborating the existence of a muscarinic- and purinergic-resistant
neurogenic component in the bladder that has not yet been fully characterized [35, 36].
Both calcium and potassium are involved in receptor-independent muscle contraction. M3
receptors also interact with Gq to elicit the release of Ca2+ from internal stores through inosi-
tol-1,4,5-trisphosphate (IP3) receptor activation [20], and muscarinic agonist induced contrac-
tions also partly depend on Ca2+ entry through Cav1.2 channels [30, 37–40]. High levels of
extracellular K+ depolarize the cell membrane and activate Cav1.2 channels, resulting in an
increased inward movement of Ca2+, which in turn activates contractile proteins [19]. Our
Fig 4. Representative trace of a frequency-response curve to EFS in detrusor smoothmuscle from (A)
control and (B) Berkeley transgenic sickle cell (SS) mice in basal tonus. Frequency-response curves to
electrical field stimulation (EFS; 1–32 Hz) (C) in detrusor smooth muscle strips from control (open circles) and
Berkeley transgenic sickle cell (SS; closed circles) mice in basal tonus. Maximal response values are
represented in panel D. Data represent the means ± SEM of N experiments. *P < 0.05 compared with control
group.
doi:10.1371/journal.pone.0133996.g004
Underactive Bladder in Sickle Mice
PLOS ONE | DOI:10.1371/journal.pone.0133996 August 4, 2015 10 / 15
findings show that DSM from SS mice present a reduction in the contractile response to both
KCl and extracellular CaCl2; suggesting that reduced extracellular Ca
2+ entry via Cav1.2 chan-
nels plays a critical role in the underactive DSM.
Reduced contractile responses to muscarinic and purinergic agonists, KCl, CaCl2, and EFS,
with impairment of the relaxation mechanism induced by isoproterenol and mirabegron, cor-
roborate the hypothesis that these animals have an atonic detrusor smooth muscle. This phar-
macological characterization of major mechanisms involved in the DSM atonia of SS mice (ex
vivo) provides pathophysiological support for the alterations in the contraction or relaxation
mechanisms of DSM during the filling and emptying phases observed in vivo: these animals
have a reduced urinary volume, suggesting urinary retention, and their urodynamic parameters
show absence of urinary bladder activity. Histomorphometric analysis revealed significant
changes in SS mice bladder structure, such as reduction of the bladder wall thickness and vol-
ume, along with reduction of wet weight. Decrease in wall thickness may explain the
impairment in bladder contractile ability, since a reduction in muscle thickness probably affects
muscle contraction. Thus, SS mice probably have an underactive urinary bladder due to atonic
DSM.
While ischemia-reperfusion injury occurs in SCD, we are not aware that chronic ischemia of
the urinary bladder has been described in these patients. Regarding mechanisms that could
explain this bladder phenotype, there is evidence that chronic bladder ischemia can cause bladder
dysfunction in atherosclerosis of the pelvic vessels [41]. This type of damage has been attributed
Fig 5. Histological sections of urinary bladder wall in normal (A-C) and Berkeley transgenic sickle cell
(SS) mice (D-I). U = urothelial cells; S = submucosa; L = lumen; M = smooth muscle; E = edema;
H = hemorrhage; Yellow Arrows: inflammatory cells. Bar = 50 μm (B, E and H) and 30 μm (C, F and I).
Hematoxylin and eosin staining.
doi:10.1371/journal.pone.0133996.g005
Underactive Bladder in Sickle Mice
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to impaired perfusion, leading to oxidative stress of the bladder wall. Excessive reactive oxygen
species production is a pathophysiological mechanism common to both atherosclerosis and
SCD, and progression frommoderate to severe bladder ischemia in atherosclerosis is thought to
cause overactive bladder syndrome in elderly patients that later progresses to symptoms of
underactivity [42]. Since SCD vaso-occlusion causes repeated cycles of ischemia-reperfusion
injury from birth, bladder ischemia might ensue earlier and more severely than in acquired pro-
gressive ischemia, possibly explaining our finding of an underactive bladder in SS mice.
Despite SS mice exhibiting an underactive bladder and severe structural abnormalities, our
analysis also revealed presence of hemorrhage, edema, and submucosal and muscular infiltra-
tion by mononuclear cells. The presence of inflammatory cells in the muscular and submucosa
layers of the bladder wall in SS mice supports the existence of a chronic inflammatory state of
the urinary bladder, which may be a morphological finding corresponding to the occurrence of
oxidative stress in the bladder a pathological mechanism underlying bladder dysfunction in
other models, such as chronic bladder ischemia in atherosclerosis [41].
UBD is rarely spontaneously reported by SCD patients to their caregivers, but clinical obser-
vations of medical complaints involving the urinary bladder start as early as childhood, with
enuresis, and continue onto adulthood with nocturia and urinary tract infections (UTIs) [4,
14]. SCD-associated UBD may contribute to impair the bladder emptying function leading to
the presence of residual urine. It is known that residual urine in a high-pressure container
causes either decompensation of the detrusor with vesicoureteral reflux or deterioration of the
bladder wall with hypertrophy and stiffness resulting in ureterovesical obstruction. The subse-
quent insufficient drainage of the upper urinary tract leads to decompensation of the ureters
and finally to chronic renal disease, the process being accelerated by urinary tract infections
(UTI; [43]). An epidemiological study of 321 children with SCD showed that 7% had a docu-
mented UTI, one third had recurrent infections, and two-thirds had a febrile UTI [5], and
most episodes of gram-negative septicemia in SCD are secondary to UTI [44]. Moreover, UTIs
are more frequent during pregnancy in women with SCD or sickle cell trait [6–8], with increas-
ing prevalence of bacteriuria and UTI according to HbS levels [43, 45, 46].
However, clinical studies have shown that SCD patients present disturbances in the urinary
bladder, such as enuresis [14, 47]. The lower urinary tract consists of the urinary bladder and
urethra. The urethra contributes to urinary continence by relaxing during the voiding phase
and contracting during urine storage phase. Urethral smooth muscle is mainly innervated by
sympathetic fibers, occasioning in the release of noradrenaline that acts on postjunctional
α1-adrenoceptors and leading to urethral contractions. This excitatory pathway is responsible
for the DSM contraction that maintains continence [25]. We herein show that SS mice exhibit
a contractile response reduction of the urethra, leading to impaired urinary continence, which
may contribute to the enuresis symptoms observed in the SCD patients.
One can expect that the urological complaints caused by SCD-associated UBD are underre-
ported and may be confused with symptoms of more prevalent urological disorders whose inci-
dence increases with age, such as urinary stress incontinence and benign prostatic hyperplasia,
particularly with this patient population’s increasing survival [4]. This might hinder the ability
of clinical observations to detect UBD specifically associated with SCD. Moreover, UBD is a
common but poorly understood lower urinary tract dysfunction that affects both genders [48],
and this animal model may contribute to further research on all aspects of UBD.
Conclusions
In summary, this study is the first to perform a detailed ex vivo evaluation of the urethra- and
detrusor-muscle functional response and urinary function in SS mice, showing evidence to
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indicate the presence of a SCD-associated UBD caused by an atonic detrusor smooth muscle,
resulting in underactive bladder and the impairment of emptying efficacy. Finally, this is the
first experimental evidence of SCD-associated UBD and data suggest that both morphological-
and urinary continence-alterations may contribute to UTIs and the enuresis reported in SCD.
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